Loading patent…
AssigneeRoyal College of Surgeons In Ireland
InventorsTracy Robson, David Grieve, Amy Short, Adrien Kissenpfennig, Marie Migaud, Rachel Bennett, Anita Yakkundi, Helen McCarthy
Estimating the term…
The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.
A method of treating obesity comprising the step of administering to a subject in need thereof, a FK506-binding protein like (FKBP-L) nucleic acid or polypeptide, wherein the FKBP-L nucleic acid or polypeptide is selected from the group consisting of:
Dependencies are inferred from the claim text.